文献速递肿瘤 PET/CT核素与放射性配体治疗

癌症免疫环境及其药物干预反应的成像:第二部分——新型PET显像剂的作用

Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
PubMed 文献 · J Nucl Med · 2020-09-04

本文综述了18F-FDG PET/CT在监测免疫治疗反应和识别免疫相关不良事件中的挑战,尤其是在治疗早期,且其在选择最佳免疫治疗类型方面作用有限。随着对免疫微环境认识的深入,新的可成像靶点不断被定义,新型放射性药物有望替代或补充18F-FDG PET/CT用于免疫治疗的选择和监测。文章讨论了进入早期临床评估的有前景的显像剂,并提出了一个推测性的常规实践应用算法,但需临床试验验证。

要点

  • 18F-FDG PET/CT监测免疫治疗反应存在挑战,尤其在治疗早期。
  • 新型PET显像剂靶向免疫细胞浸润特征或肿瘤微环境。
  • 提出了推测性算法,但需临床试验验证。

核心结论

  • 新型PET显像剂有望替代或补充18F-FDG PET/CT用于免疫治疗的选择和监测。

研究设计与样本

  • 本文为综述,检索范围未在摘要中明确报告。

主要发现

  • 18F-FDG PET/CT在解释免疫治疗结果方面存在挑战,尤其在治疗早期。
  • 18F-FDG PET/CT在选择最佳免疫治疗类型方面作用有限。
  • 靶向免疫细胞浸润特征或肿瘤微环境抑制性成分的显像剂进入早期临床评估。

临床怎么用

  • 作者提出一个推测性算法,探讨新型显像剂如何在常规实践中使用,但需临床试验验证。

局限性

  • 所提算法为推测性,需临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although 18F-FDG PET/CT is widely available and is increasingly being used to monitor response to immunotherapy and simultaneously identify immune-related adverse events, there are several challenges in interpreting the results of this investigation, especially early in the course of treatment. It also has limited utility in selecting the optimal type of immunotherapy. As knowledge about immune contexture increases, new targets that may be amenable to imaging are being defined. These exciting advances, coupled with increasingly sophisticated methods for generating radiopharmaceuticals, provide the potential for either replacing or complementing 18F-FDG PET/CT in the selection and monitoring of immunotherapy. Approaches include imaging specific characteristics of immune cell infiltrates or aspects of the tumor microenvironment that are known to be associated with suppression of the innate and adaptive immune response. Following a large body of preclinical work, promising agents that are entering into early clinical evaluation are discussed. We suggest a speculative algorithm as to how these might be used in routine practice, subject to validation in clinical trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Iravani A, Hicks RJ. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. J Nucl Med. 2020. PMID: 32887755. doi:10.2967/jnumed.120.248823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。